Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

595.40 +4.27 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 388,667
Open 587.76
Bid (Size) 593.80 (1)
Ask (Size) 596.99 (1)
Prev. Close 591.13
Today's Range 586.17 - 597.00
52wk Range 538.01 - 747.42
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review
The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in... 
Via Benzinga

Performance

YTD
-5.06%
-5.06%
1 Month
-5.54%
-5.54%
3 Month
-14.75%
-14.75%
6 Month
-5.06%
-5.06%
1 Year
+2.26%
+2.26%

More News

Read More
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
Via Investor's Business Daily
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
Via Benzinga
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
Via Benzinga
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
Via Benzinga
Regeneron Pharmaceuticals Whale Trades Spotted
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today
Via Benzinga
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Via Investor's Business Daily
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Via Benzinga
Sunshine Biopharma States It Is Developing COVID Antiviral That Could Play Important Role In Treating Endemic COVID
Via Benzinga
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
Stock Market Rally Falls As Fed Signals More Big Rate Hikes; Salesforce, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Markets Rise Amid Strength In Tech, Software
Via Benzinga
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer
Via Investor's Business Daily
Regeneron Pharmaceuticals Whale Trades Spotted
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Via Benzinga
7 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
NASDAQ:REGN Investor Notice: Investigation over Potential Wrongdoing at Regeneron Pharmaceuticals, Inc.
Via SBWire
As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats
Via Benzinga
United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds
Via Investor's Business Daily
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.